MRK : Summary for Merck & Company, Inc. Common St - Yahoo Finance

U.S. Markets open in 4 hrs 55 mins

Merck & Co., Inc. (MRK)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
63.34+0.15 (+0.24%)
At close: 4:00PM EDT
People also watch
PFEJNJBMYLLYPG
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close63.19
Open63.20
Bid0.00 x
Ask0.00 x
Day's Range62.88 - 63.40
52 Week Range52.44 - 66.80
Volume10,184,989
Avg. Volume10,776,173
Market Cap173.9B
Beta0.94
PE Ratio (TTM)44.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.88 (2.98%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 hours ago

    UPDATE 2-Roche MS drug Ocrevus approved by FDA after 3-month delay

    The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).

  • 10 Biggest Recent Accounting Scandals in America
    Insider Monkey2 days ago

    10 Biggest Recent Accounting Scandals in America

    The 10 biggest recent accounting scandals in America have shaken the nation and affected investor confidence. Though not all scandals are the same, they tend to lead to large investor losses and depending on the magnitude of the scandal, may even affect confidence in the financial system at large. Corporate accounting scandals are by no […]

  • Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma
    Zacks2 days ago

    Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma

    Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).